Researchers at Baylor College of Medicine report that low expression levels of a key gene makes estrogen receptor-positive (ER+) breast cancer more sensitive to treatment with CDK4/6 inhibitor drugs. These findings, published in Science Translational Medicine , could pave the way for the development of molecular tests that can predict a patient’s likelihood to respond to this form of treatment, enabling a novel precision approach to treating one of the most common types of breast cancer.

Because their growth depends on estrogen, ER+ breast cancers are often treated with endocrine agents that block the estrogen receptor. While CDK4/6 inhibitors are commonly combined with endocrine therapy to lower the chances of relapse, there is still limited understanding of which patients benefi

See Full Page